BackgroundWith the development of technology and the internet, social networks gained momentum quickly and play a central role in daily activities. Despite this, there is a public health concern over excessive or problematic social media use. There is also a debate whether excessive social media use should be considered as a behavioral addiction characterized by impulsivity or an impulse control disorder characterized by compulsivity. The goal of this study is to use neurocognitive tasks to investigate impulsivity and compulsivity among excessive social media users compared with non-excessive users.MethodThe study included 79 participants (age range 18 to 37), divided into two groups: 34 participants who excessively use social media (Mean Age = 23.03, SD = 2.71) and 45 participants who do not excessively use social media (Mean Age = 25.47, SD = 4.3). Participants filled out a demographic questionnaire, questionnaires on social media use, impulsivity, compulsivity, anxiety, and depression. They performed computerized cognitive tasks: GO/NO-GO (with Facebook and traffic sign pictures), Experimental Delay Discounting (EDT), and the Wisconsin Card Sorting Test (WCST).ResultsExcessive users of social media exhibited a lower ability to delay gratification on the EDT, indicating impulsivity. They made fewer non-perseverative errors on the WCST, which indicated high flexibility and test shifting, which is a contradicting evidence for compulsivity. Furthermore, on the GO/NO-GO task, individuals who excessively use social media made more omission errors in response to the “Facebook” sign compared to traffic signs (GO condition), indicating impaired selective attention. Finally, they also showed higher subjective ratings of anxiety, depression, impulsivity, and compulsivity.DiscussionThe results of this study provide evidence for impulsivity indicated by delay discounting tendency, which supports the behavioral addiction model, impaired selection attention and lack of evidence for compulsivity in excessive social media users. Further research on neurocognitive function in excessive social media users is required in order to determine whether it should be considered a behavioral addiction or an impulse control disorder.
The Download: China’s AI drama factory and the WHO’s missing health targets
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
How Chinese short dramas became AI content machines
China’s short drama industry is fueled by bite-sized, melodramatic, and smutty shows built for smartphone scrolling. Now, many are being made entirely with AI: no actors, camera operators, cinematographers, or CGI specialists required.
An average of 470 AI-generated short dramas were released every day in January. Production timelines have shrunk from months to weeks, while costs have dropped by up to 90%. Storytelling is also increasingly driven by performance data.
The format is rapidly expanding overseas while reshaping the work of writers and production crews. Read the full story on AI’s dramatic impact on China’s short drama industry.
—Caiwei Chen
The world is on track to miss its health targets
The World Health Organization’s latest global statistics report reads less like a progress update than a warning sign. Progress on some of the world’s biggest health threats is stalling, and in some cases reversing altogether.
There were 1.3 million new HIV cases in 2024, malaria is resurging, vaccination rates are slipping in the Americas, and 42.8 million children are suffering from severe malnutrition. The world is now far off track from meeting many of the UN’s major health goals by 2030.
Here’s what the numbers reveal about the state of global health.
—Jessica Hamzelou
This story is from The Checkup, our weekly newsletter giving you the inside track on all things biotech. Sign up to receive it in your inbox every Thursday.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 As their trial goes to the jury, Musk and Altman face lying accusations
Lawyers hammered the rivals’ credibility in their closing arguments. (WSJ $)
+ Musk was accused of “selective amnesia.” (Reuters $)
+ The pair are in court over OpenAI’s future. (MIT Technology Review)
+ And their trial has made everyone look bad. (Wired $)
2 AI data centers are straining America’s power grid
Nevada is redirecting electricity from Lake Tahoe to AI. (Ars Technica)
+ Utah is getting a giant data center despite water shortage fears. (Guardian)
+ No one wants a data center in their backyard. (MIT Technology Review)
3 OpenAI is mulling legal action against Apple over its ChatGPT integration
It hasn’t got the expected benefits from its deal with Apple. (Bloomberg $)
+ OpenAI is frustrated by the promotion of the ChatGPT integration. (NYT $)
4 Anthropic has agreed terms for a $30 billion funding deal
At a $900 billion valuation, which leapfrogs OpenAI’s. (The Information $)
+ Dragoneer, Greenoaks, Sequoia, and Altimeter are leading the round. (FT $)
6 Washington and Beijing will hold formal talks on AI safety
They’ll discuss guardrails on AI. (CNBC)
+ And a protocol to stop nonstate actors getting powerful models. (NYT $)
5 Alphabet and Amazon are using “unprecedented” borrowing to fund AI
They’re tapping the foreign debt market at new levels. (FT $)
+ People can’t agree on what the AI bubble is. (MIT Technology Review)
7 Big Tech has turned to Sesame Street to deflect scrutiny of screen use
Sparking accusations of encouraging children’s tech dependence. (Reuters $)
8 Anthropic’s feud with the White House threatens other businesses
Figma and Tenable say it will harm their ability to sell software. (Bloomberg $)
9 Autonomous agents staged a digital crime spree during a safety test
The “AI Bonnie and Clyde” then deleted themselves. (Guardian)
10 A poop app analysis app offered to sell photos of users’ stools
The images were used for AI training. (404 Media)
Quote of the day
“It’s like we don’t exist.”
—Danielle Hughes, North Lake Tahoe resident and CEO of Tahoe Spark, tells Fortune that residents are being sidelined as their energy supplier prioritizes data centers.
One More Thing
LIZ ISLES/ALL TECH IS HUMAN
The rise of the tech ethics congregation
Just before Christmas, a pastor preached a gospel of morals over money to several hundred members of his flock. But the preacher wasn’t religious, and his congregation wasn’t a church. It was All Tech Is Human, a nonprofit devoted to ethics and responsibility in tech.
Founded in 2018, the organization has built a fast-expanding community for people who believe technology should focus less on profits and more on the public interest. It’s also drawing people searching for meaning and connection in a digital world.
Find out why thousands of people are turning to tech ethics communities for guidance and connection.
—Greg M. Epstein
We can still have nice things
A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ Go behind the scenes of the new Lucas Museum of Narrative Art.
+ Marvel at this robot folding and launching paper planes as quickly as possible.
+ Watch the moving moments rescued animals reunite with the humans who saved them.
+ Peer into the heart of a barred spiral galaxy in this stunning new capture from the James Webb Space Telescope.
Context-dependent interaction between oxytocin gene polymorphisms and alcohol dependence in modulating negative emotions during acute alcohol withdrawal in adult males
ObjectiveThe importance of multiple gene-environment interaction (G × E) has been highlighted in understanding the etiology of negative emotions. This study examines the impact of oxytocin (OXT) polymorphisms (rs2740210, rs6133010, and rs2740209) in combination with alcohol dependence on anxiety and depression symptoms during acute alcohol withdrawal under different social and environmental contexts.MethodA total of 414 Chinese Han male adults undergoing acute alcohol withdrawal were recruited. Participants provided blood samples for genotyping, self-reported measures of depression and anxiety, assessments of alcohol dependence severity, and demographic information regarding social and environmental contexts.ResultsResults revealed a positive correlation between severity of alcohol dependence and symptoms of depression and anxiety, while oxytocin polymorphism did not have a direct effect on depressive and anxiety symptoms. A significant interaction between OXT polymorphism (rs2740210 and rs2740209) and alcohol dependence in relation to anxiety symptoms solely among adults living with family and/or those who were married was observed. Further analyses indicate that the GG and CC genotypes are risk genotypes, while the T allele (rs2740210) and G allele (rs2740209) are non-risk alleles in the interaction between OXT genotypes (rs2740210, rs2740209) and alcohol dependence on anxiety among the aforementioned participants.ConclusionsThese findings provide evidence for distinct G × E interaction effects on anxiety and depression symptoms during acute alcohol withdrawal, supporting the weak diathesis-stress model. Furthermore, the study highlights the importance of considering environmental factors when investigating the role of oxytocin as a biological substrate underlying social bonding and the regulation of negative emotions.
Contact Lenses Show Promise for Depression
Using specialized contact lenses to stimulate the brain could offer a novel route to treating depression, preclinical research suggests.
The research, in mice, demonstrates how wearable neuromodulation devices can provide a versatile platform for mood and other brain disorders.
It brings eye-based neurotherapies a step closer towards clinical reality and reveals the feasibility of using contact lenses as a bioelectronic strategy for the treatment of depression.
The findings appear in the latest issue of Cell Reports Physical Science.
“Our work opens up an entirely new frontier of treating brain disorders through the eye,” said lead author Jang-Ung Park, PhD, from Yonsei University.
“We believe this wearable, drug-free approach holds tremendous promise for transforming how depression and other brain conditions are treated, including anxiety, drug addiction, and cognitive decline.”
Depression is increasingly recognized as a disorder involving structural and functional abnormalities in brain networks.
Conventional treatments—such as pharmacological therapy, electroconvulsive therapy, and deep brain stimulation—target these abnormalities but can be invasive and are often limited in their efficacy or tolerability.
Park and team note that the eye provides a compelling gateway for indirect brain modulation due to its embryological derivation from the brain and extensive connectivity.
Studies also suggest that visual impairment with higher prevalence of depression, further recognizing the importance of the eye-brain axis.
To investigate this avenue further, the researchers developed a contact lens that uses transcorneal electrical stimulation (TES) based on temporal interference (TI) to stimulate the brain. This delivers two electrical signals to the retina, which only become active where they intersect, allowing specific areas of the brain to be targeted.
The platform circumvents the invasiveness and limited tolerability of conventional brain stimulation therapies by using the retina as a precise interface for the eye-brain axis.
Electrodes made from ultrathin layers of gallium oxide and platinum allow the lens to be flexible and transparent, conforming to the cornea and preserving natural vision.
The researchers examined the efficacy of the lenses in a stress-induced mouse model that recapitulated key behavioral and biological features associated with depression.
Depressed mice received either no intervention, temporal interference, or the SSRI fluoxetine and were compared with control mice that were not depressed before and after treatment. Machine learning was applied for comprehensive efficacy evaluation.
The team reported that the lenses restored behavioral, neural, and biological deficits in depression.
TI-TES enhanced behavioral resilience, restored prefrontal-hippocampal oscillatory synchrony, and normalized depression-related biomarkers.
When machine-learning integration was used to integrate behavior, brain activity, and biomarkers, it consistently grouped the mice with lenses with the non-depressed control mice rather than the untreated depressed mice.
The researchers acknowledge their research is in its early stages, and that the current study employed a wired configuration to ensure precise waveform control and stimulation stability during proof-of-concept validation.
“Like any new medical technology, our contact lenses will need to go through rigorous clinical evaluation in patients before reaching the market,” said Park.
“Next, we plan to make the lens fully wireless, test it for long-term safety in larger animals, and personalize the stimulation for each user before advancing into clinical trials in patients.”
The post Contact Lenses Show Promise for Depression appeared first on Inside Precision Medicine.
Establishing AI and data sovereignty in the age of autonomous systems
When generative AI first moved from research labs into real-world business applications, enterprises made a tacit bargain: “Capability now, control later.” Feed your proprietary data into third-party AI models, and you will get powerful results. But your data passes through systems you do not own, under governance you do not set. The protections you rely on are only as durable as the provider’s next policy update.
Now, with generative AI established in everyday business operations and sophisticated new agentic AI systems advancing every day, companies are reevaluating the terms of that deal.
“Data is really a new currency; it’s the IP for many companies,” says Kevin Dallas, CEO of EDB, echoing a recurrent anxiety from customers. “The big concern is, if you’re deploying an AI-infused application with a cloud-based large language model, are you losing your IP? Are you losing your competitive position?”
That question is now fueling a movement toward reclaiming both the data and AI systems that have rapidly become part of core business infrastructure. AI and data sovereignty, which refers to breaking dependence on centralized providers and establishing genuine control over models and data estates, it is an urgent priority for many companies, says Dallas, citing internal EDB data: “70% of global executives believe they need a sovereign data and AI platform to be successful.”
The idea of AI sovereignty is becoming a global policy conversation. NVIDIA CEO Jensen Huang recently spoke about the need for such a shift at the World Economic Forum’s annual meeting at Davos in January 2026: “I really believe that every country should get involved to build AI infrastructure, build your own AI, take advantage of your fundamental natural resource—which is your language and culture—develop your AI, continue to refine it, and have your national intelligence be part of your ecosystem.”
This report explores how enterprises are pursuing sovereignty over their models and data estates in an era of rapid AI adoption. Drawing on a survey conducted by EDB of more than 2,050 senior executives and a series of interviews with industry experts, the research confirms that the sovereignty movement on the enterprise level is already well underway.
This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff. It was researched, designed, and written by human writers, editors, analysts, and illustrators. This includes the writing of surveys and collection of data for surveys. AI tools that may have been used were limited to secondary production processes that passed thorough human review.
Targeted Ultrasound Could Offer Alternative to Chronic Pain Medication
A new study has shown that targeting ultrasound stimulation to brain regions involved in processing pain can induce long-lasting changes in brain activity, significantly reducing pain perception. Published in Nature Communications, these findings point at a novel non-invasive strategy to treat chronic pain.
“Our study represents an important first step in understanding how this technology can non-invasively stimulate deep brain regions involved in pain processing,” said Sam Hughes, PhD, senior lecturer in pain neuroscience at the University of Exeter. “We found that targeting a specific brain region involved in pain processing can alter how pain is perceived and change how this area communicates with other parts of the brain’s pain network. The next stage of our research will be to test whether this approach can help people living with chronic pain.”
Hughes and colleagues used transcranial ultrasound stimulation (TUS), a low-intensity neuromodulation technique, to target the dorsal anterior cingulate cortex (dACC), a brain region implicated in chronic pain. The study recruited a total of 32 healthy volunteers, who were treated either with TUS or a sham while putting their right hand in a cold gel to trigger pain due to the low temperature. All participants were asked to rate the severity of the pain they were feeling and underwent MRI and MRS scans to monitor the physiological changes caused by the treatment.
Results showed that, while TUS had no immediate effect on pain intensity, participants reported a significant reduction in pain from 28 to 55 minutes after the stimulation, suggesting it can trigger a delayed analgesic effect. At the physiological level, TUS was found to disrupt the relationship between temperature and pain intensity, increasing the connectivity between the dACC and other brain regions involved in pain modulation and changing the concentration of the GABA neurotransmitter within the dCC.
“The study aimed to characterize how transcranial ultrasound stimulation interacts with—and potentially also alters—the brain’s processing of pain,” said Sophie Clarke, PhD, postdoctoral research fellow at the University of Plymouth and lead author of the study. “Understanding these mechanisms will be very important to support the next steps in understanding whether the stimulation can be effective in helping patients with chronic pain.”
Previous research at the University of Plymouth had shown the potential benefits of TUS for psychiatric conditions including anxiety, depression, and addiction. This study shows these benefits could extend beyond neurological disorders and one day offer a non-invasive treatment option for those experiencing chronic pain due to conditions such as fibromyalgia, back pain, and arthritis, or recovering after cancer treatment.
“Having shown the use of ultrasound can yield positive results for people with a variety of neurological conditions, we wanted to explore what it could mean for those living with chronic pain,” said Elsa Fouragnan, PhD, director of the University of Plymouth’s Brain Research and Imaging Centre (BRIC) and Centre for Therapeutic Ultrasound (CENTUS). “Most of us know someone experiencing chronic pain, and there are very few treatments that deliver any form of long-term benefit. The findings of this new work are really promising, and we are already building on it to assess whether TUS could be a beneficial and non-invasive therapeutic treatment.”
The post Targeted Ultrasound Could Offer Alternative to Chronic Pain Medication appeared first on Inside Precision Medicine.
Direct modulation of human GABA-A α1β2γ2 receptors by the endocannabinoid 2-arachidonoylglycerol: implications for cannabinoid-related ligands and limitations for anxiolytic drug development
Anxiety disorders are associated with impaired inhibitory neurotransmission mediated by γ-aminobutyric acid type A (GABA-A) receptors. Although benzodiazepines remain effective anxiolytics, their clinical utility is limited by sedation, cognitive impairment, tolerance, and dependence, prompting the search for mechanistically distinct GABAergic modulators. Among cannabinoid-related molecules, the strongest evidence for direct GABA-A receptor modulation concerns the endocannabinoid 2-arachidonoylglycerol (2-AG), which potentiates recombinant human α1β2γ2 receptors through residues located in the M4 helix of the β2 subunit. Here, we review the structural architecture, biophysical properties, and pharmacological profile of the human GABA-A α1β2γ2 isoform as the relevant molecular framework for evaluating this mechanism, while discussing the broader relevance of cannabinoid-related ligands and selected phytocannabinoids without assuming mechanistic equivalence. We further assess the hypothesis that 2-AG reaches the β2-M4 site through a membrane-access route and identify five conceptual barriers that currently limit translation of this mechanism into anxiolytic drug development: supraphysiological effective concentrations, unresolved synaptic-versus-extrasynaptic actions, uncertain subtype selectivity, incomplete validation of lipid-environment effects, and lack of clinical evidence linking this mechanism to anxiolysis in humans. We conclude that direct modulation through β2-M4 defines a mechanistically intriguing allosteric pathway distinct from benzodiazepine action; however, its location on a shared β2 subunit and the micromolar concentrations required for modulation represent substantial obstacles to the rational design of anxioselective agents based on this mechanism.
Romanian male patients with the dual diagnosis of schizophrenia and alcohol use disorder: a prospective study of clinical, social, and treatment-related factors affecting quality of life
BackgroundSchizophrenia frequently co-occurs with alcohol use disorder (AUD), resulting in a complex clinical profile associated with poor functional outcomes and reduced quality of life (QoL). Although both conditions independently impair psychosocial functioning, few studies have examined the combined effects of clinical, social, and treatment-related factors on QoL in patients with this dual diagnosis.MethodsThis prospective observational study included 88 male inpatients diagnosed with schizophrenia and comorbid AUD and who were followed over a 6-month period. Quality of life was assessed using the World Health Organization Quality of Life–BREF (WHOQoL–BREF). The clinical variables included severity of psychotic symptoms (Positive and Negative Syndrome Scale), alcohol use severity (Michigan Alcohol Screening Test), and treatment characteristics. Social and personal factors, such as self-care capacity, social support, education, and legal problems, were also evaluated. Multivariable regression analyses were conducted to identify predictors of QoL at baseline and follow-up.ResultsAt baseline, higher QoL was significantly associated with greater self-care capacity, social support, and higher positive symptom scores, while the need for antipsychotic treatment was associated with lower QoL. At the 6-month follow-up, better QoL was predicted by greater self-care capacity, higher educational level, and receipt of anti-craving medication. By contrast, negative and general psychopathology, medico-legal problems, and the need for antidepressant treatment were associated with poorer QoL. Alcohol use severity, as measured by the MAST, was not independently associated with QoL at either timepoint.ConclusionsIn patients with schizophrenia and comorbid AUD, QoL is shaped by a complex interaction of clinical severity, functional capacity, and treatment-related factors. Beyond symptom control, interventions targeting self-care, social functioning, and integrated addiction treatment appear essential to improve long-term outcomes. These findings support the implementation of a multidimensional, recovery-oriented approach for the management of patients with the dual diagnosis.
The Download: a Nobel winner on AI, and the case for fixing everything
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
Three things in AI to watch, according to a Nobel-winning economist
A few months before he won the Nobel Prize in economics in 2024, Daron Acemoglu published a paper that earned him few fans in Silicon Valley. He argued that AI would give only a small boost to US productivity and would not eliminate the need for human work.
Two years later, Acemoglu’s measured take has not caught on. The technology has advanced quite a bit since his cautious predictions, but the data is still largely on his side.
MIT Technology Review spoke with him to understand if any of the latest developments have changed his thesis. Here are the three things Acemoglu is paying closest attention to in AI right now.
—James O’Donnell
This story is from The Algorithm, our weekly newsletter giving you the inside track on all things AI. Sign up to receive it in your inbox every Monday.
The case for fixing everything
Stewart Brand, the counterculture icon and tech industry legend, considers maintenance a “civilizational” act. His new book argues that taking responsibility for maintaining something, whether a motorcycle, a monument, or the planet, can be radical.
Brand argues that maintainers haven’t gotten the laurels they deserve—and he’s right. Yet his vision of maintenance often feels solitary: profound, but more about personal fulfillment than tending to a shared world or making it better.
Read the full review of his handsome new book, Maintenance: Of Everything, Part One.
—Lee Vinsel
Lee Vinsel is an associate professor of science, technology, and society at Virginia Tech, a cofounder of The Maintainers, and the host of Peoples & Things, a podcast about human life with technology.
This story is from the latest edition of our print magazine, which is all about nature. Subscribe now to read the full issue and receive future print copies once they land.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 The first zero-day exploit built by AI has been discovered
Google spotted and stopped the attempted “mass exploitation event.” (CNBC)
+ The hackers used AI to discover an unknown bug. (NYT $)
+ AI-powered hacking has exploded into an industrial-scale threat. (Guardian)
+ New tools are simplifying online crime. (MIT Technology Review)
2 OpenAI just launched its answer to Claude Mythos
Daybreak patches vulnerabilities before attackers find them. (The Verge)
+ Sam Altman said it will “continuously secure software.” (Gizmodo)
+ It will rival Anthropic’s Claude Mythos, which arrived a month ago. (BBC)
+ OpenAI is allowing wider access to its cyber models than Anthropic. (CNBC)
3 Trump is heading to China to spread the gospel of American tech
While taking cues from Beijing’s more stringent approach. (Guardian)
+ But investors want Trump and Xi to stay out of AI’s way. (Reuters $)
+ Elon Musk and Tim Cook are joining him on the trip this week. (BBC)
4 Ilya Sutskever has testified on Sam Altman’s “pattern of lying”
OpenAI co-founder Sutskever took the stand in the Altman v. Musk trial. (BI)
+ He said he spent a year gathering proof of Altman’s dishonesty. (Reuters $)
+ But he also added to OpenAI’s defense. (Wired $)
+ While Satya Nadella called attempts to remove Altman “amateur city.” (FT $)
+ Here’s what happened last week in the trial. (MIT Technology Review)
5 A new hantavirus vaccine is in the works
Moderna and Korea University are developing an mRNA vaccine. (Wired $)
+ Here’s what you need to know about the cruise ship outbreak. (MIT Technology Review)
6 Texas has sued Netflix over alleged data harvesting and “addictive” design
AG Ken Paxton accuses Netflix of secretly collecting and selling user data. (Quartz)
+ And spying on children while deliberately fostering addiction. (Guardian)
7 A data center guzzled 30 million gallons of water—and no one noticed
The curious case serves as a warning for other data center projects. (Ars Technica)
8 Europe is reportedly selling spyware to human rights abusers
EU states allegedly sold the tech to countries violating rights. (Bloomberg $)
9 The US government’s AI vetting announcement has mysteriously vanished
It had detailed a security test agreement with Google, xAI, and Microsoft. (Gizmodo)
10 Amazon staff are using AI for pointless tasks just to inflate usage scores
In a bid to impress managers. (FT $)
+ An AI expert says we should stop using AI so much. (MIT Technology Review)
Quote of the day
“This is like the cheating husband complaining about the cheating wife.”
—Anupam Chander, a professor of law and technology at Georgetown Law School, tells the New York Times that Elon Musk’s hypocrisy over OpenAI becoming a for-profit company will undermine his courtroom battle with Sam Altman.
One More Thing
STUART BRADFORD
How sounds can turn us on to the wonders of the universe
For decades, astronomy has relied on visual information to make sense of the cosmos: images, charts, and graphs. Now, some researchers are trying something different: listening to the universe.
Using sonification, the process of turning information into sound, they’re helping blind and visually impaired researchers explore the cosmos—and even uncover patterns that might otherwise go unnoticed. The approach is spreading beyond astronomy into fields like climate science, navigation, and education.
Discover how sound could make science more accessible—and even more revealing.
—Corey S. Powell
We can still have nice things
A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ This musical mashup beautifully blends LCD Soundsystem with Twin Peaks.
+ Match your speculative ideas to sci-fi stories with the Extrapolated Futures Archive.
+ A live-action animation Coyote vs. ACME is coming soon—and the first trailer just dropped.
+ Want to surf elsewhere in the galaxy? Here’s what it would be like to catch waves on distant planets.
Therapeutic Interventions Targeted at Problematic Use of Digital Technology: Systematic Review and Meta-Analysis of Evidence
Background: Problematic use of digital technology has increased across the world. Despite growing research, evidence on treatment effectiveness across digital behaviors remains fragmented. Objective: This study aimed to systematically evaluate and compare the effectiveness of therapeutic interventions targeted at problematic use of digital technology across various behavioral domains. Methods: A systematic review and meta-analysis was conducted in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines (PROSPERO: CRD420251052442). Electronic searches of PubMed, Scopus, and Embase (up to April 2025) were conducted. It identified 125 eligible studies, including 73 randomized controlled trials (RCTs), 32 non-RCTs, 14 pre-post studies, and 6 pilot studies. The interventions that were assessed in these studies included psychological therapies, digital or web-based programs, exercise-based interventions, pharmacological treatments, neuromodulation, parent-focused programs, virtual reality–based interventions, educational programs, and multicomponent approaches. Random-effects meta-analyses using standardized mean differences (SMDs) were performed. Results: For problematic internet use, psychological treatments showed a strong effect (effect size=−2.68; <.001). Digital interventions also showed significant benefit (effect size=−1.16; <.001). For smartphone addiction, psychological treatments (effect size=−1.49; <.001) and exercise-based programs (effect size=−3.07; =.001) showed significant improvement. For gaming disorder, psychological treatments showed improvement (effect size=−1.01; =.02), but results were mixed. There were limited studies to calculate pooled results for social media addiction, pornography use, gambling, screen time, and over-the-top content watching. No treatment studies were found for problematic over-the-top content watching. High heterogeneity and evidence of small-study effects were observed in several studies. Conclusions: Overall, structured psychological therapies showed the most consistent benefit. These findings support structured interventions that aim for control of use and reduce cues linked to high use. Evidence remains limited for several emerging digital behaviors. More high-quality studies are needed in clinical settings and for less-studied forms of digital addiction.
